Search
for
Sort by
Research 15
- Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
- Prostate cancer update: 2007
- Prostate cancer update: 2007
- Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation
- Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- Redefining hormone resistance in prostate cancer
- Recent discoveries and developments of androgen receptor based therapy for prostate cancer
- Clinical Development of Topoisomerase-Interactive Drugs
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
- Mitoxantrone
- Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review
- Evolution, classification, structure, and functional diversification of steroid 5α-reductase family in eukaryotes
- RGDSP-functionalized peptide hydrogel stimulates growth factor secretion via integrin αv/PI3K/AKT axis for improved wound healing by human amniotic mesenchymal stem cells